
LRRK2-IN-1
CAS No. 1234480-84-2
LRRK2-IN-1 ( LRRK 2-IN-1 )
产品货号. M10936 CAS No. 1234480-84-2
一种有效的 LRRK2 抑制剂,对野生型/G2019S 突变体 LRRK2 的 IC50 分别为 13 nM/6 nM(测定中为 0.1 mM ATP)。
纯度: >98% (HPLC)






规格 | 价格/人民币 | 库存 | 数量 |
5MG | ¥486 | 有现货 |
![]() ![]() |
10MG | ¥697 | 有现货 |
![]() ![]() |
25MG | ¥1434 | 有现货 |
![]() ![]() |
50MG | ¥2600 | 有现货 |
![]() ![]() |
100MG | ¥4560 | 有现货 |
![]() ![]() |
200MG | 获取报价 | 有现货 |
![]() ![]() |
500MG | 获取报价 | 有现货 |
![]() ![]() |
1G | 获取报价 | 有现货 |
![]() ![]() |
生物学信息
-
产品名称LRRK2-IN-1
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述一种有效的 LRRK2 抑制剂,对野生型/G2019S 突变体 LRRK2 的 IC50 分别为 13 nM/6 nM(测定中为 0.1 mM ATP)。
-
产品描述A potent LRRK2 inhibitor with IC50s of 13 nM/6 nM for wild-type/G2019S mutant LRRK2 repectively (0.1 mM ATP in the assay); shows modest activity against LRRK2 A2016T (IC50=2.45 uM) and LRRK2 A2016T+G2019S mutant (IC50=3.08 uM); also inhibits DCLK1 (IC50=2.61 nM) and 2 (IC50=45 nM); induces dephosphorylation of Ser910 and Ser935 of LRRK2 and alters the cytoplasmic localisation of LRRK2.
-
体外实验Wild-type and G2019S transduction results in 2.5 fold higher TR-FRET signal which can be inhibited by LRRK2-IN-1 in a dose-dependent manner with IC50 values of 0.08 μM and 0.03 μM, respectively. LRRK2-IN-1 possessed an IC50 of 45 nM for inhibition of DCLK2 and exhibits an IC50 of greater than 1 μM when evaluated in biochemical assays for AURKB, CHEK2, MKNK2, MYLK, NUAK1, and PLK1. LRRK2-IN-1 is confirmed to inhibit MAPK7 with an EC50 of 160 nM. LRRK2-IN-1 induces a dose dependent inhibition of Ser910 and Ser935 phosphorylation accompanied by loss of 14-3-3 binding to both wild type LRRK2 and LRRK2[G2019S] stably transfected into HEK293 cells. LRRK2-IN-1 is moderately cytotoxic with IC50 of 49.3 μM in HepG2 cells. LRRK2-IN-1 exhibits genotoxicity in the presence and absence of S9 at 15.6 and 3.9 μM, respectively. LRRK2-IN-1 inhibits proliferation, migration, and induces cell death with hallmarks of apoptosis of HCT116 and AsPC-1 cells.
-
体内实验LRRK2-IN-1 (100 mg/kg, i.p.) induces dephosphorylation of LRRK2 in the kidney of the mice. Peritumoral injection of LRRK2-IN-1 (100 mg/kg) results in a significant decrease in tumor volume and weight of AsPC-1 tumor xenografts.
-
同义词LRRK 2-IN-1
-
通路Autophagy
-
靶点LRRK2
-
受体DCLK1|DCLK2|LRRK2(A2016T)|LRRK2(G2019S)|LRRK2(WT)
-
研究领域Neurological Disease
-
适应症——
化学信息
-
CAS Number1234480-84-2
-
分子量570.6852
-
分子式C31H38N8O3
-
纯度>98% (HPLC)
-
溶解度10 mM in DMSO
-
SMILESO=C1N(C)C2=CN=C(NC3=CC=C(C(N4CCC(N5CCN(C)CC5)CC4)=O)C=C3OC)N=C2N(C)C6=CC=CC=C16
-
化学全称6H-Pyrimido[4,5-b][1,4]benzodiazepin-6-one, 5,11-dihydro-2-[[2-methoxy-4-[[4-(4-methyl-1-piperazinyl)-1-piperidinyl]carbonyl]phenyl]amino]-5,11-dimethyl-
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Deng X, et al. Nat Chem Biol. 2011 Apr;7(4):203-5.
2. Weygant N, et al. Mol Cancer. 2014 May 6;13:103.
3. Luerman GC, et al. J Neurochem. 2014 Feb;128(4):561-76.